<DOC>
	<DOCNO>NCT02228460</DOCNO>
	<brief_summary>Primary Objective : To assess safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , exploratory efficacy GZ/SAR402671 enzyme replacement therapy treatment-naïve adult male patient diagnose Fabry disease .</brief_summary>
	<brief_title>Evaluate Safety , Pharmacodynamics , Pharmacokinetics , Exploratory Efficacy GZ/SAR402671 Treatment-naïve Adult Male Patients With Fabry Disease</brief_title>
	<detailed_description>The total duration study per patient 7 8 month patient enter plan extension study approximately 13 14 month patient enter plan extension study . A 2-year extension study plan eligible patient .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Inclusion criterion : The patient ≥18 year age &lt; 50 year age . The patient male . The patient provide sign informed consent . The patient confirm diagnosis Fabry disease document leukocyte α Galactosidase A ( αGAL ) activity &lt; 4 nmol/hr/mg leukocyte ( preferred assay ; result central laboratory ) plasma αGAL &lt; 1.5 nmol/hr/mL ( result central laboratory ) . The patient plasma globotriaosylsphingosine ( lysoGL3 ) great equal 65 ng/mL . The patient never treat Fabry diseasespecific treatment . If patient reninangiotensinaldosterone system ( RAAS ) blockers antidepressant , dose stable ( ie , prescribe dose frequency ) least immediate 3 month prior screen . Exclusion criterion : The patient estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m^2 use ( Chronic Kidney Disease Epidemiology Collaboration ) CKDEPI . The patient median urine protein/creatinine ratio ( PCR ) ≥0.5 g/g ( median 3 overnight urine collection . Collection 3 sample must occur 4 7 day , sample must collect within 15 day period ) . All 3 sample must collect regardless result result available prior Day 1 . The patient undergone kidney transplant . The patient either active history clinically significant organic disease ( exception symptom relate Fabry disease ) , include clinically significant cardiovascular , hepatic , pulmonary , hematologic , neurological renal disease , medical condition , serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude participation trial . The patient abnormal liver function ( serum total bilirubin &gt; upper limit normal , serum alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 2.0 time upper limit normal ) . The patient , accord World Health Organization ( WHO ) Grading cortical cataract ( COR ) &gt; onequarter lens circumference ( Grade COR2 ) posterior subcapsular cataract ( PSC ) &gt; 2 mm ( Grade PSC2 ) . Patients nuclear cataract exclude . The patient currently receive potentially cataractogenic medication . The patient receive strong moderate inducer inhibitor Cytochrome P450 3A4 ( CYP3A4 ) per Food Drug Administration ( FDA ) classification within 14 day prior enrolment within 5 time elimination halflife PD halflife medication , whichever longer . The patient schedule inpatient hospitalization , include elective surgery , study . The patient positive result follow test : hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( antiHCV ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 antiHIV2 Ab ) . Patients positive hepatitis B surface antibody ( HBsAb ) test history prior hepatitis B immunization eligible criterion meet ( ie , negative test : HBsAg , hepatitis B core antibody [ HBcAb ] , hepatitis C virus antibody [ HCVAb ] ) . The patient participate study involve investigational drug within past 30 day start trial . The patient unwilling comply requirement protocol . The patient sexually active man willing use 2 form birth control include barrier method study 6 week last treatment IMP . The patient history ongoing clinically significant cardiac arrhythmia , define either atrial fibrillation , sustain nonsustained ventricular tachycardia . The patient contraindication magnetic resonance imaging ( MRI ) . The patient one follow central nervous system exclusion criterion : Acute stroke , within 3 month screen visit . History seizure . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>